Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507936 | 0.92 | GLP1R (0.50) | F2GLP1RAPLNR | |
| SCHEMBL16507946 | 0.92 | GLP1R (0.50) | F2GLP1RAPLNR | |
| SCHEMBL16508102 | 0.91 | F2 (0.46) | OPRM1OPRD1OPRK1F2GLP1R | |
| SCHEMBL16508044 | 0.91 | PSMB5 (0.49) | F2GLP1RPSMB5APLNR | |
| SCHEMBL16507751 | 0.91 | NPY5R (0.47) | OPRM1OPRD1OPRK1F2GLP1R | |
| SCHEMBL16507772 | 0.90 | APLNR (0.51) | OPRM1OPRD1OPRK1F2GLP1R | |
| SCHEMBL16508053 | 0.89 | APLNR (0.52) | F2GLP1RPSMB5APLNR | |
| SCHEMBL16507916 | 0.88 | APLNR (0.52) | F2GLP1RPSMB5APLNR | |
| SCHEMBL16507834 | 0.88 | GLP1R (0.50) | F2GLP1RAPLNR | |
| SCHEMBL16508132 | 0.86 | NPY5R (0.48) | OPRM1OPRD1OPRK1F2KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | OPRM1 1747/4885OPRD1 1000/4885OPRK1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.